Systematic review of randomized trials for XXXX treated with percutaneous ablation therapies.

@entity1 @entity5 @entity409 @entity8681 @entity157 @entity1068
According to the American Association for the Study of @entity409 guidelines, percutaneous @entity1068 injection ( @entity8681 ) is a safe and highly effective treatment for @entity157 ( @entity157 ) and should be the standard against which any new therapy is compared. The primary purpose of this study was to identify survival benefit of any percutaneous ablation therapy as compared with @entity8681 in the treatment of @entity1 with unresectable @entity157 . The secondary endpoints were @entity5 response, local @entity5 progression, and complications. Randomized controlled trials that compared pecutaneous ablative therapies with @entity8681 were included. MEDLINE, the Cochrane Library, CANCERLIT, and manual search from 1978 to July 2008 were used. To control the potential heterogeneity, the random effects model of DerSimonian and Laird was used for a meta-analysis. Egger's test was performed to test a potential publication bias. We identified seven randomized controlled trials (RCTs), but only four RCTs including 652 @entity1 that compared radiofrequency ablation (RFA) with @entity8681 met the inclusion criteria to perform a meta-analysis assessing 3-year survival. A meta-analysis of the four RCTs demonstrated a significant improvement in 3-year survival favoring RFA over @entity8681 (odds ratio 0.477, 95% confidence interval 0.340-0.670; P < 0.001). Heterogeneity among the four trials was not significant (Q = 4.586; P= 0.205). Egger's test revealed that the publication bias was not significant (P = 0.647). However, the number of @entity1 included in the analysis was insufficient for a robust meta-analysis of @entity5 response. The @entity5 progression or major complication was not unified among the trials included in the meta-analysis. CONCLUSION: RFA demonstrated significantly improved 3-year survival status for @entity1 with @entity157 , when compared to @entity8681 .
